ライフサイエンスコーパス: seroreactivity

1 29 (17%) patients had positive Western blot seroreactivity.

2 ns, while <50% of Caucasians with SSc showed seroreactivity.

3 the sera met conventional criteria for HTLV seroreactivity.

4 ral DNA and once (at the later time) for VLP seroreactivity.

5 ate antibody to hepatitis E virus (anti-HEV) seroreactivity, 5000 US blood donors were tested for ant

6 We measured immunoglobulin G seroreactivity against 10 polyomaviruses (BKPyV, JCPyV,

7 Seroreactivity against alphaA-, alphaB-, or betaB1-, but

8 Seroreactivity against alphaB and betaB1 was significant

9 rpose of this study was to determine whether seroreactivity against betaB1 or other specific purified

10 d M. bovis-infected cattle with little to no seroreactivity against M. kansasii- and M. avium subsp.

11 requently have gastrointestinal symptoms and seroreactivity against secretory granules of Paneth cell

12 Seroreactivity against SOX1 and 2 was consistently highe

13 The significance of anti-HEV seroreactivity among persons without an international tr

14 (NYC) has declined to a record low, syphilis seroreactivity among women jailed in NYC is approximatel

15 e first time an association between a unique seroreactivity and disease.

16 eason, children maintained this differential seroreactivity and recognized additional intracellular P

17 lts showed a strong association between HIAP seroreactivity and the detection of autoantibodies to do

18 ent measures of sensitization history (e.g., seroreactivity), and allow the simultaneous assessment o

19 structural features, antigenic composition, seroreactivity, and immunogenicity of purified HCV-LPs.

20 Our data also indicate a strong linkage of seroreactivity between apparently distinct serotypes tha

21 Additionally, SV40 seroreactivity confirmed by competitive-inhibition exper

22 HIV-1 assay shows 100% agreement with known seroreactivity for a collection of 82 HIV Ab-positive an

23 and cancer patient sera showed anti-NY-LU-12 seroreactivity in 2 of 21 allogeneic lung cancer patient

24 he prevalence of latent yaws with high-titer seroreactivity in a subgroup of children 1 to 15 years o

25 ion protein showed frequent immunoglobulin A seroreactivity in CD (54% of patients), but infrequent s

26 ; P<0.001) with a near-absence of high-titer seroreactivity in children 1 to 5 years of age.

27 G was developed and revealed high-titer MDH seroreactivity in culture-confirmed cases and 5 addition

28 f Leishmania braziliensis, and evaluated the seroreactivity in exposed individuals in search for expo

29 ical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women.

30 In this study we show low seroreactivity in humans against simian- (sAd11, sAd16)

31 vity in CD (54% of patients), but infrequent seroreactivity in patients with ulcerative colitis, othe

32 the accurate determination of PERV-specific seroreactivity in porcine xenograft recipients.

33 Until the basis for HEV seroreactivity in such areas is elucidated, anti-HEV res

34 The high incidence of BA21 seroreactivity in these patients suggests that exposure

35 No new rapid plasmin reagin (RPR) seroreactivity in young children is required for certifi

36 Seroreactivity increased with age, similar to the age-sp

37 l antibiotic therapy; i.e., EMIBA identified seroreactivity indicating a clinical circumstance requir

38 If the seroreactivity is confirmed by more specific tests, then

39 The seroreactivity levels in swine serum samples and the nuc

40 e (LD), serologic testing is insensitive and seroreactivity may reflect active or past infection.

41 ects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 ma

42 The seroreactivity of p35 was evaluated by immunoblotting ag

43 The seroreactivity patterns against these five proteins coul

44 patients with active ongoing infection from seroreactivity persisting long after clinically successf

45 alysis found that only upper-quintile cHsp60 seroreactivity remained a significant predictor of CAD a

46 hese genes, PFD1140w, and this protein shows seroreactivity similar to that of VAR2CSA domains.

47 ertile women had significantly greater Hsp10 seroreactivity than acutely infected women, indicating a

48 r chitinolytic activity and slightly greater seroreactivity than the bacterially expressed recombinan

49 SV40 seroreactivity therefore may reflect zoonotic exposure.

50 era collected from 14 states were tested for seroreactivity to a cultured isolate of the human granul

51 These data suggest that seroreactivity to a given type reflects mainly type-spec

52 nd immunoblot studies revealed no consistent seroreactivity to a recombinant RD protein by H. pylori-

53 ity to any type was associated with elevated seroreactivity to all others.

54 In contrast, seroreactivity to any type was associated with elevated

55 nce of endocarditis were included because of seroreactivity to B. vinsonii antigens and uncharacteriz

56 The high prevalence of bacteremia and seroreactivity to Bartonella spp. in gray foxes suggests

57 tribution of HLA class II Ags along with the seroreactivity to Campylobacter jejuni were investigated

58 Seroreactivity to cutaneous HPV types was highly prevale

59 The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/

60 y infants expressed the highest level of IgG seroreactivity to intestinal microbiota antigens.

61 ne function, the authors assessed individual seroreactivity to meningioma tumor-associated antigens a

62 mensal microbiota, mostly based on increased seroreactivity to microbial proteins.

63 Moderate to high frequencies of seroreactivity to PARV4 (63% and 18% in chimpanzees and

64 Seroreactivity to PfEMP1 fragments was higher in adults

65 ntrolling for classical CAD risk factors and seroreactivity to the other antigens (cHsp60 OD, P=0.005

66 Seroreactivity to the panel of antigens was significantl

67 through screening for oral HPV infection or seroreactivity to viral antigens.

68 HIAP seroreactivity was also strongly associated with the det

69 Seroreactivity was associated with detection of HPV-16 D

70 HIV-1 p24 gag seroreactivity was found in 27 (35%) of 77 patients with

71 Seroreactivity was independently associated with oral co

72 tectable antibodies to CT antigens, and this seroreactivity was restricted to NY-ESO-1.

73 Seroreactivity was significantly associated with younger

74 HPV-16 seroreactivity was strongly associated with HPV-16 DNA d

75 Seroreactivity was strongly influenced by antigenic vari

76 ylated hemagglutinin enhanced stalk-directed seroreactivity while dampening the head response in immu

77 Finally, seroreactivity with recombinant orf 73 protein exactly p

78 he basis of its specificity, defined as high seroreactivity with sera from individuals infected with

79 hat were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years afte